DSP-4 prevents dopamine receptor priming by quinpirole

Pharmacology Biochemistry and Behavior

Volumn 84, Issue 1, 2006, Pages 3-7

  Nowak, PrzemysŁaw ^a   Labus, Łukasz ^a   Kostrzewa, Richard M ^b   Brus, Ryszard ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b East Tennessee State University   (United States)

Author keywords

Dopamine; Dopamine receptor; DSP 4; Quinpirole; Rats; Receptor priming; Receptor supersensitivity; Yawning

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BIRTH; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; NEWBORN; NEWBORN PERIOD; NONHUMAN; NORADRENERGIC SYSTEM; ONTOGENY; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; SENSITIZATION; YAWNING;

ANIMALS; BEHAVIOR, ANIMAL; BENZYLAMINES; DRUG ANTAGONISM; FEMALE; PREGNANCY; QUINPIROLE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE;

EID: 33745652738     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.03.024     Document Type: Article

References (48)

1. Antelman S.M., and Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science 195 4279 (1977) 646-653
2. Booze R.M., Hall J.A., Cress N.M., Miller S.D., and Davis J.N. DSP-4 treatment produces abnormal tyrosine hydroxylase immunoreactivity in rat hippocampus. Exp Neurol 101 (1988) 75-86
3. Brus R., Kostrzewa R.M., Perry K.W., and Fuller R.W. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J Pharmacol Exp Ther 268 (1994) 231-237
4. Brus R., Plech A., and Kostrzewa R.M. Enhanced quinpirole responses in rats lesioned neonatally with 5,7-dihydroxytryptamine. Pharmacol Biochem Behav 50 (1995) 649-653
5. 2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotox Res 5 (2003) 329-338
6. Brus R., Nowak P., Labus Ł., Bortel A., Da{ogonek}browska J., and Kostrzewa R.M. Neonatal lesion of noradrenergic neurons in rat brain; interaction with the dopaminergic system. Pol J Pharmacol 56 (2004) 232-233 (Suppl.)
7. Bymaster FP., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
8. Damsma G., Bottema T., Westerink B.H., Tepper P.G., Dijkstra D., Pugsley T.A., et al. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 249 (1993) R9-R10
9. 1 receptors in caudate-putamen subregions in high-yawning Sprague-Dawley rats. Synapse 56 (2005) 69-73
10. Fritschy J.M., Geffard M., and Grzanna R. The response of noradrenergic axons to systemically administered DSP-4 in the rat, an immunohistochemical study using antibodies to noradrenaline and dopamine-β-hydroxylase. J Chem Neuroanat 3 (1990) 309-323
11. Gong L., and Kostrzewa R.M. Supersensitized oral response to a serotonin agonist in neonatal 6-OHDA treated rats. Pharmacol Biochem Behav 41 (1992) 621-623
12. Gong L., Kostrzewa R.M., Fuller R.W., and Perry K.W. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261 (1992) 1000-1007
13. 1 receptors in neonatal 6-OHDA-lesioned rats. Dev Brain Res 76 (1993) 59-65
14. Gong L., Kostrzewa R.M., Perry K.W., and Fuller R.W. Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76 (1993) 233-238
15. 1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats. J Neurochem 63 (1994) 1282-1290
16. Gower A.J., Berendsen H.H.G., Princen M.M., and Broekkamp C.L.E. The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol 103 (1984) 81-89
17. Jacobowitz D., and Kostrzewa R. Selective action of 6-hydroxydopa on noradrenergic terminals: mapping of preterminal axons of the brain. Life Sci I 10 (1971) 1329-1342
18. Jaim-Etcheverry G. 2-Chloro-ethylamines (DSP-4 and xylamine). Toxic actions on noradrenergic neurons. In: Kostrzewa R.M. (Ed). Highly selective neurotoxins. Basic and clinical applications (1998), Humana Press, Totowa, New Jersey, USA 131-140
19. Jaim-Ethceverry G., and Zieher L.M. DSP-4, a novel compound with neurotoxic effect on noradrenergic neurons of adult and developing rats. Brain Res 188 (1980) 513-523
20. Kostowski W., Samanin R., Bareggi S.R., Mark V., Garattini S., and Valzelli L. Norepinephrine could influence serotonin neurons in dorsal raphe projecting to substantia nigra. Brain Res 82 (1974) 178-182
21. Kostrzewa R.M. Dopamine receptor supersensitivity. Neurosci Biobehav Rev 1 (1995) 1-17
22. 3 mediated event?. Life Sci 48 (1991) PL-129
23. Kostrzewa R.M., and Brus R. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol Biochem Behav 39 (1991) 517-519
24. 2 receptors. Eur J Pharmacol 183 (1990) 1411-1412
25. 1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol Biochem Behav 39 (1991) 677-682
26. Kostrzewa R.M., Gong L., and Brus R. Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp 53 (1992) 31-41
27. Kostrzewa R.M., Brus R., Perry K.W., and Fuller R.W. Age-dependence of a 6-hydroxy-dopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76 (1993) 87-93
28. Kostrzewa R.M., Brus R., Rykaczewska M., and Plech A. Low-dose quinpirole ontogenically sensitizes to quinpirole-induced yawning in rats. Pharmacol Biochem Behav 44 (1993) 487-489
29. Kostrzewa R.M., Reader T., and Descarries L. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70 (1998) 889-898
30. 2 agonist priming in intact and dopamine-lesioned rats. Neurotox Res 6 6 (2004) 457-462
31. Labus Ł., Nowak P., Bortel A., Da{ogonek}browska J., and Brus R. Neonatal lesion of the central noradrenergic neurons and activity of the central dopamine system examined by behavioral methods in adult rats. Pol J Pharmacol 56 (2004) 242 (Suppl.)
32. Longoni R., Spina L., and Di Chiara G. Permissive role of D-1 receptor stimulation by endogenous dopamine for the expression of postsynaptic D-2 mediated behavioral responses. Yawning in rats. Eur J Pharmacol 134 (1987) 163-173
33. Magnusson O., Nilsson L.B., and Westerland D. Simultaneous determination of dopamine, DOPAC and homovanillic acid. J Chromatogr 221 (1980) 237-247
34. Nowak P., Bortel A., Da{ogonek}browska J., Labus Ł., Brus R., and Kostrzewa R.M. Effect of neonatal DSP-4 administration on biogenic amine levels and amphetamine-induced release into microdialysates of adult rat frontal cortex. Pol J Pharmacol 56 (2004) 248-249 (Suppl.)
35. Oświe{ogonek}cimska J., Brus R., Szkilnik R., Nowak P., and Kostrzewa R.M. 7-OH-DPAT, unlike quinpirole, does not prime a yawning response in rats. Pharmacol Biochem Behav 67 (2000) 11-15
36. Plech A., Brus R., Kalbfleisch J.H., and Kostrzewa R.M. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology 119 (1995) 466-473
37. Ross S.B. Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Brit J Pharmacol 58 (1976) 521-527
38. Ross S.B., and Renyi A.L. On the long-lasting inhibitory effect of N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of noradrenaline. J Pharm Pharmacol 28 (1976) 458-459
39. Ross S.B., Jahansson J.G., Lindborg B., and Dahlbom R. Cyclizing compounds. I. Tertiary N-(2-bromobenzyl)-N-haloalkylamines with adrenergic blocking actions. Acta Pharm Suec 10 (1973) 29-42
40. 1 antagonist, SCH 23390. Psychopharmacology (Berl.) 91 (1987) 330-333
41. 3) as a target for neuroleptics. Nature 347 (1990) 146-151
42. Stoessl A.J., Dourish C.T., and Iversen S.D. Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology (Berl.) 93 (1987) 336-342
43. Szechtman H., Sulis W., and Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112 (1998) 1475-1485
44. Szechtman H., Eckert M.J., Tse W.S., Boersma J.T., Bonura C.A., McClelland J.Z., et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2 1 (2001) 4
45. Szumlinski K.K., Goodwill A.M., and Szechtman H. Locomotor sensitization to quinpirole in rats: effects of drug abstinence and sex. Psychopharmacology (Berl.) 152 (2000) 304-311
46. Ungerstedt U. Norepinephrine fibers from locus coeruleus to neocortex may influence dopamine function indirectly by modulating a descending corticostriatal pathway. Acta Physiol Scand Suppl 367 (1974) 1-48
47. Yamada K., Nagashima M., Kimura H., Matsumoto S., and Furudawa T. Possible involvement of differing classes of dopamine D-2 receptors in yawning and stereotypy in rats. Psychopharmacology (Berl.) 100 (1990) 141-144
48. Zhang X., Zuo D.M., and Yu P.H. Neuroprotection by R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus coeruleus. Neurosci Lett 186 (1995) 45-48